With hundreds of daily COVID-19 deaths in Hong Kong, severe and critical illness have become common clinical manifestations. What comorbidities best predict disease progression, and what are the leading causes of death?

Meanwhile, as access for various therapeutics widens, what are the recommendations and outcomes for new antivirals such as nirmatrelvir/ritonavir and molnupiravir?

In our latest webinar, our speakers will give you the latest updates on these vital developments, followed by a moderated panel discussion where you can follow up with clinical questions.

This webinar is open to all healthcare professionals and is conducted in English. This is not a CME-accredited activity.

Date: 1 April 2022 (Fri)
Time: 18:30-20:00 HKT


How to predict severe COVID-19 at presentation and what do patients with severe disease die of?
Dr Kenny King-Chung CHAN
Specialist in Intensive Care
Chief of Service (ICU), Tuen Mun Hospital/Pok Oi Hospital
MBChB, FHKCA, FHKCA(IC), FHKAM(Anaesthesiology)

Arrival of two new oral antivirals – light at the end of the tunnel?
Dr Andrew Tin-Yau WONG
Specialist in Infectious Disease
Honorary Consultant, Infectious Disease Centre & Department of Medicine & Geriatrics, Princess Margaret Hospital
MBBS(HK), MPH (Johns Hopkins), MSc Infectious Disease, LSTMH (Lond), DTM&H (Lond), Dip G-U M (LAS), PGDipClinDerm (QMUL), FRCP (Lond), FFPHM (UK), FHKCP, FHKAM(Med)


Dr Brian Kin-Chung AU
General Practitioner

Dr Ada Wai-Chi LIN
Specialist in Infectious Disease


Enquiry: +852 3893 6222  (WhatsApp message/call)

Co-organised with

Supported by

pfizer postlogo